Oculis完成了第三阶段对糖尿病血管水肿进行新眼滴试验的注册。 Oculis completes enrollment for Phase 3 trials of new eye drop for diabetic macular edema.

Oculis是一家生物制药公司,已在其对OCS-01的DIAMOND第3阶段试验中收治了800多名病人,这是对糖尿病肌肉水肿(DME)的一种新的眼滴治疗。 Oculis, a biopharmaceutical company, has finished enrolling over 800 patients in its DIAMOND Phase 3 trials for OCS-01, a new eye drop treatment for diabetic macular edema (DME). 如果获得批准,OCS-01将成为DME的第一个眼滴,为病人提供新的治疗选择。 If approved, OCS-01 would be the first topical eye drop for DME, offering a new treatment option for patients. 预计2026年第二季度将获得试验结果,随后可能提交给美国FDA. Results from the trials are expected in the second quarter of 2026, with a potential U.S. FDA submission to follow.